Arvinas Inc (ARVN)

Apr 04, 2025

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study - Yahoo Finance

Apr 04, 2025

Apr 04, 2025

Arvinas : MoneyGram and Mastercard collaborate to advance digital money movement - MarketScreener

Apr 04, 2025

Apr 04, 2025

Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s - Yahoo

Apr 04, 2025

Apr 04, 2025

Arvinas Presents First-in-Human Data For ARV-102 In Neurodegenerative Diseases, Stock Down - Nasdaq

Apr 04, 2025

Apr 04, 2025

Arvinas stock plunges to 52-week low at $6.46 amid market rout - Investing.com

Apr 04, 2025

Apr 04, 2025

Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2 - MarketScreener

Apr 04, 2025

Apr 04, 2025

Arvinas Holding Company Unveils Promising ARV-102 Trial Results - TipRanks

Apr 04, 2025

Apr 04, 2025

Arvinas Presents First-in-Human Data for Investigational - GlobeNewswire

Apr 04, 2025

Apr 04, 2025

Arvinas touts healthy volunteer data for Parkinson’s disease PROTAC - Endpoints News

Apr 04, 2025

Apr 03, 2025

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth - Yahoo Finance

Apr 03, 2025

Apr 03, 2025

Edmond DE Rothschild Holding S.A. Takes Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Apr 03, 2025

Apr 02, 2025

Arvinas, Inc. (NASDAQ:ARVN) Short Interest Update - MarketBeat

Apr 02, 2025

Apr 01, 2025

BIT Capital GmbH Has $5.05 Million Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat

Apr 01, 2025

Mar 31, 2025

Arvinas (NASDAQ:ARVN) Hits New 52-Week LowHere's What Happened - MarketBeat

Mar 31, 2025

Mar 29, 2025

Where are the Opportunities in (ARVN) - news.stocktradersdaily.com

Mar 29, 2025

Mar 27, 2025

Arvinas stock hits 52-week low at $7.91 amid market challenges - Investing.com India

Mar 27, 2025

Mar 27, 2025

Arvinas stock hits 52-week low at $7.91 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases - GlobeNewswire

Mar 27, 2025

Mar 27, 2025

Groundbreaking First Human Data: New PROTAC Drug Takes Aim at Parkinson's Disease - Stock Titan

Mar 27, 2025

Mar 26, 2025

Arvinas (NASDAQ:ARVN) Shares Down 5.1%Time to Sell? - MarketBeat

Mar 26, 2025

Mar 25, 2025

Arvinas FY2025 EPS Forecast Increased by Cantor Fitzgerald - MarketBeat

Mar 25, 2025

Mar 24, 2025

Noah Berkowitz Sells 8,658 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock - MarketBeat

Mar 24, 2025

Mar 23, 2025

Arvinas (NASDAQ:ARVN) Trading Up 4%Here's Why - MarketBeat

Mar 23, 2025

Mar 21, 2025

Wedbush Brokers Raise Earnings Estimates for Arvinas - MarketBeat

Mar 21, 2025

Mar 20, 2025

Wedbush Has Positive Outlook for Arvinas Q1 Earnings - MarketBeat

Mar 20, 2025

Mar 19, 2025

Arvinas chief medical officer sells $74,372 in common stock By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance

Mar 19, 2025

Mar 19, 2025

Arvinas chief medical officer sells $74,372 in common stock - Investing.com India

Mar 19, 2025

Mar 19, 2025

Arvinas Chief Medical Officer Sells Shares to Cover Tax Obligations - TradingView

Mar 19, 2025

Mar 19, 2025

(ARVN) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 19, 2025

Mar 18, 2025

Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds? - Yahoo Finance

Mar 18, 2025

Mar 17, 2025

Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook By Investing.com - Investing.com Australia

Mar 17, 2025

Mar 17, 2025

Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook - Investing.com

Mar 17, 2025

Mar 17, 2025

Arvinas (NASDAQ:ARVN) Price Target Cut to $12.00 by Analysts at Morgan Stanley - MarketBeat

Mar 17, 2025

Mar 17, 2025

Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance

Mar 17, 2025

Mar 17, 2025

The Goldman Sachs Group Downgrades Arvinas (NASDAQ:ARVN) to Neutral - MarketBeat

Mar 17, 2025

Mar 17, 2025

Arvinas (NASDAQ:ARVN) Given New $32.00 Price Target at Guggenheim - MarketBeat

Mar 17, 2025